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Neural stem cells (NSCs) generate neurons and glial cells through-
out embryonic and postnatal brain development. The role of S-
palmitoylation (also referred to as S-acylation), a reversible
posttranslational lipid modification of proteins, in regulating the fate
and activity of NSCs remains largely unknown. We used an unbiased
screening approach to identify proteins that are S-acylated in mouse
NSCs and showed that bonemorphogenic protein receptor 1a (BMPR1a),
a core mediator of BMP signaling, is palmitoylated. Genetic manip-
ulation of S-acylated sites affects the localization and trafficking of
BMPR1a and leads to altered BMP signaling. Strikingly, defective
palmitoylation of BMPR1a modulates NSC function within the mouse
brain, resulting in enhanced oligodendrogenesis. Thus, we identified
a mechanism regulating the behavior of NSCs and provided the
framework to characterize dynamic posttranslational lipid modifica-
tions of proteins in the context of NSC biology.
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oligodendrogenesis
The activity and fate of neural stem cells (NSCs) in the de-veloping and adult mammalian brain are tightly regulated by
a plethora of cell intrinsic and extrinsic mechanisms ensuring
that proper numbers and types of neuronal and glial cells are
produced (1). By defining cellular and transcriptional programs
that direct the fate of NSCs, substantial progress has been made
to understand how NSCs are regulated within their endogenous
niches (2–4). However, little is known of how posttranslational
modifications (PTMs) of stem cell–expressed proteins affect NSC
activity and subsequent fate choices. PTMs, such as phosphory-
lation, ubiquitination, sumoylation, acetylation, glycosylation, and
lipidation among others, have been shown to affect the localiza-
tion, activity, and stability of a large number of proteins, allowing
for fast and partially reversible modification of protein function
(5–10). Thus, PTMs represent critical regulators of protein func-
tion in a variety of cell types, allowing for fast signal diversification
and refined cellular responses to exogenous cues (11). Many
proteins are modified by the attachment of lipid moieties such as
myristoylation, prenylation, and palmitoylation (also referred to as
S-acylation) that modulate protein function (5). Among all known
lipid modifications, S-acylation represents the only known re-
versible form of lipid modification that has been shown to play a
pivotal role in protein trafficking, stability, and function (5, 12).
16-Carbon palmitate residues are transferred onto cysteines of
target proteins via palmitoyl-acyltransferases (zDHHC1–24) and
can be dynamically removed by acyl-protein thioesterases (for
example, APT1-2) (13). Indeed, recent data suggest that reversible
palmitoylation is involved in a large variety of biological processes
such as growth of Arabidopsis thaliana, melanocortin signaling in
the skin, synaptic function in the adult central nervous system, and
many others (5, 14–16). Thus, over the last years large efforts have
been undertaken to define the palmitoyl proteome in a variety of
cell types and tissues (17).
Results
Identification of Palmitoylated Proteins in Mammalian NSCs. To
identify a role for protein palmitoylation in mammalian stem cell
function, we used an acyl-biotin exchange (ABE) assay to discover
proteins that are S-acylated in NSCs isolated from the hippo-
campus of 8-wk-old mice (Fig. 1A). NSCs were lysed, and the
protein samples were divided into 2 fractions. In the +hydroxyl-
amine (+HAM) sample, the palmitate residue was cleaved off and
exchanged with biotin. The −HAM condition served as a negative
control. After the ABE reaction was completed, streptavidin
beads were used to enrich for biotinylated proteins. Proteins
enriched from +HAM and −HAM conditions were identified using
mass spectrometry (MS) (Fig. 1B and SI Appendix, Fig. S1A).
Proteins with a significant and at least 4-fold higher abundance in
the +HAM sample were considered candidate proteins. With this
approach, we identified 347 palmitoylated proteins in cultured
NSCs (Fig. 1B), with an expected enrichment of identified pro-
teins to be associated with membrane localization and function
using Gene Ontology (GO) localization and molecular function
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Fig. 1. Identification of S-acylated proteins in neural stem cells. (A) Schematic describing the enrichment strategy and mass spectrometry-based workflow
used for the identification of S-acylated proteins. Mass spectrometry and a label-free analysis were used for identification and quantification of proteins.
Protein lysates were divided into 2 fractions. In the +HAM +Biotin condition, the palmitate was cleaved off and exchanged with a biotin. The −HAM +Biotin
condition controls for unspecific binding. Streptavidin beads were then used to enrich for biotinylated proteins, followed by mass spectrometry-based
identification. NEM, N-ethylmaleimide. (B) ABE enrichment coupled with mass spectrometry–based analysis identified 347 potentially S-acylated proteins
(blue). Proteins that were less than 4-fold or not significantly enriched between the −HAM and +HAM conditions are shown in black. (C) Probing
identified proteins for GO. “Localization” and “Molecular function” show that a substantial fraction of candidate proteins is associated with membrane
compartments (blue, enriched candidates; black, enriched and nonenriched proteins). (D) Comparison of candidates with the SwissPalm database for
S-acylated mouse proteins. Of the identified candidate proteins, 21.39% had not been described previously as S-acylated (dark gray). (E ) Enrichment and
background intensities (blue) of previously confirmed S-acylated proteins identified in the NSC dataset. CANX, calnexin; FLOT1, flotillin-1; GRIA2, AMPA
receptor 2. (F) Enrichment and background intensities (blue) of proteins validated in this study. NUP210, nucleoporin 210. Error bars represent mean ± SD.
*P < 0.05, **P < 0.01, ***P < 0.001.














analysis (Fig. 1C). Supporting the validity of the assay, we were
able to identify previously validated S-acylated proteins (Fig. 1 D
and E). Remarkably, 21% of the identified candidate proteins had
not previously been described as palmitoylated (Fig. 1D). Given
that palmitoyl-proteome screening approaches may yield false-
positive results (18), we used protein-specific ABE assays and an
alternative method (metabolic labeling of palmitate residues [19])
to verify S-acylation of selected candidate proteins such as
NUP210 and VAMP7 (vesicle-associated membrane protein 7)
(Fig. 1F and SI Appendix, Figs. S1 B–H and S2A), thereby con-
firming the validity of the unbiased screening results.
BMPR1a Is Palmitoylated at Multiple Cysteines by zDHHC20. One of
the candidate proteins we identified was the bone morphogenic
protein receptor 1a (BMPR1a), which together with other com-
ponents mediates canonical and noncanonical BMP signaling (Fig.
1F) (20, 21). BMP signaling plays a pivotal role in brain devel-
opment and NSC behavior and has been associated with a large
number of related biological processes, among them cell growth, cell
differentiation, and cancer (22, 23). We confirmed palmitoylation
of BMPR1a by tagging the endogenous Bmpr1a gene with
GFP using CRISPR/Cas9 technology, allowing for efficient pull-
down of BMPR1a in NSCs and subsequent ABE analysis (Fig.
2A and SI Appendix, Fig. S2B). Analogously, we confirmed palmi-
toylation of BMPR1a by tagging the endogenous BMPR1a with a
hemagglutinin (HA) tag in mouse embryonic stem cells (ESCs) that
were subsequently differentiated into NSCs and analyzed using
metabolic labeling of palmitoylation sites within BMPR1a (SI Ap-
pendix, Fig. S2 C–F). Computational analyses suggested 5 cysteine
residues to be palmitoylated within the BMPR1a protein sequence
(24). However, using an acyl-PEG (methoxypolyethylene glycol)
exchange assay, allowing for determination of the number of S-
acylated cysteines, we found that BMPR1a has 3 functional pal-
mitoylation sites (cysteines C173, C175, and C180), which
are located close to the transmembrane domain of the receptor
(Fig. 2 B and C). Directed mutagenesis showed that S-acylation
was absent when cysteine residues were exchanged into alanines
from the overexpressed BMPR1a protein (Fig. 2 B and C and SI
Appendix, Fig. S2 G and H). Importantly, exchange of palmi-
toylated cysteines into alanines did not affect binding to the
BMP4 ligand, as shown by immunoprecipitation of BMPR1a
followed by mass spectrometry of bound proteins (Fig. 2D). We
also detected single spectral counts of the interaction partner
BMPR2; however, they were not enough to draw any quantita-
tive conclusions. Immunoprecipitated tdTomato samples were
used to control for unspecific binding. Coimmunoprecipitation of
overexpressed HA-tagged BMPR1a or BMPR1a C173/175A to-
gether with FLAG-tagged BMPR1a or BMPR2 in NSCs showed
that BMPR1a C173/175A was still able to dimerize with BMPR1a
and BMPR2 (SI Appendix, Fig. S3A). We next aimed to identify
which of the 24 known palmitoyl-acyltransferases (zDHHC1–24)
(25) mediates palmitoylation of BMPR1a. We found zDHHC20
to colocalize with BMPR1a (Fig. 2E). Notably, we found over-
expression of zDHHC20 to be sufficient to enhance S-acylation of
BMPR1a (Fig. 2F), thus identifying a palmitoyl-acyltransferase
that transfers palmitate residues onto BMPR1a.
Palmitoylation of BMPR1a Alters Its Function. We next probed the
functional relevance of BMPR1a palmitoylation by testing if
acylation-deficient BMPR1a proteins are sufficient to rescue the
complete loss of the function proliferation phenotype of BMPR1a
in NSCs (26). Given their positioning within BMPR1a, we ana-
lyzed C173/175A and C180A exchanges separately. As expected,
we found that CRISPR/Cas9-mediated deletion of BMPR1a re-
duced proliferation of NSCs in response to BMP4 exposure, as
measured using 5-ethynyl-2’-deoxyuridine (EdU) pulse labeling
(SI Appendix, Fig. S3 B and C). Whereas wild-type and C180A
overexpression normalized proliferation, the proliferation upon
C173/175A overexpression was not rescued (SI Appendix, Fig.
S3B). Consistent with this, we found that overexpression of C173/
175A was not sufficient to transduce canonical BMP signaling, as
measured by luciferase assays with BMP response elements
(BREs) (SI Appendix, Fig. S3D) (27). Notably, overexpression of
zDHHC20 was able to promote canonical BMP signaling in vitro
(SI Appendix, Fig. S3E). This finding suggests that palmitoylation
of cysteine residues C173/175 is required for canonical BMPR1a
function, at least in vitro.
To analyze how palmitoylation of BMPR1a affects NSCs
in vivo, we modified acylation sites within BMPR1a and aimed to
generate mouse models harboring single (C180A) or double
(C173/175A) mutants, again exchanging the palmitoylated cyste-
ines with non-S-acylatable alanines. However, it turned out that
C173/175A double mutants could not be obtained, most likely due
to early embryonic lethality: out of 767 injected and transferred
zygotes, we did not obtain a single viable correct double mutant
mouse. This is consistent with the failure of C173/175A BMPR1a
to rescue the full BMPR1a knockout in vitro (SI Appendix, Fig.
S3B), as full knockouts of BMPR1a die at embryonic day E9.5
(28). However, we were able to generate C180A single mutants
(Fig. 3A) and detected expression of BMPR1a using immunohis-
tochemistry of BMPR1a in NSCs in the embryonic and adult brain
(Fig. 3A and SI Appendix, Fig. S3F), as described before (26, 29).
Thus, we next analyzed how palmitoylation of BMPR1a at posi-
tion C180 affects its localization and function. Strikingly, we found
that embryonic NSCs isolated from embryonic day 17.5 (E17.5)
brains of C180A mutant mice showed reduced surface expression
of the BMPR1a receptor (Fig. 3B) without affecting overall ex-
pression levels (Fig. 3C). In addition, fluorescence recovery after
photobleaching (FRAP) analysis revealed an increase in the im-
mobile fraction of overexpressed BMPR1a C180A compared to
control BMPR1a (Fig. 3D). In FRAP experiments, the total re-
covery of fluorescence after photobleaching is influenced by mo-
bile and immobile fractions of the BMP receptor. The mobile
fraction undergoes exchange with the photobleached area, whereas
the immobile fraction does not. Moreover, we found a robust re-
duction in endocytosis of BMPR1a in C180A mutant cells (Fig.
3E). Together, these findings indicate that palmitoylation of
BMPR1a at position C180 is required for proper localization and
mobility of the BMPR1a receptor (30).
Palmitoylation of C180 Affects Noncanonical BMP Signaling. To in-
vestigate the effects on BMP signaling in C180A mutant cells, we
next analyzed signaling activity in proliferating and differentiat-
ing BMP4-stimulated cells isolated from C180A mutant mice
and controls. We found that stimulation with BMP4 successfully
promoted canonical BMP signaling in C180A-derived cells and
control cells, as measured by levels of phosphorylated SMAD1/5
(SI Appendix, Fig. S3 G and H). Corroborating these results,
we also found BMP4-dependent induction of inhibitor of
differentiation 1-4 (Id1-4) gene transcripts at comparable levels
in C180A compared to control cells as measured using digital
droplet qPCR (SI Appendix, Fig. S3 I and J). This is consistent
with the finding that overexpression of C180A does not prohibit
canonical BMP signaling as measured using an BRE-dependent
luciferase assay (SI Appendix, Fig. S3D). However, the C180A
mutation caused a decrease in noncanonical, active extracellular
signal-regulated kinase 1/2 (ERK1/2) in nonstimulated and BMP4-
stimulated NSCs derived from C180A mice and controls (Fig. 3F)
and an increase in active ERK1/2 during in vitro differentiation
of C180A-derived cells (SI Appendix, Fig. S3K), which is known
to promote oligodendrocyte differentiation (31). These findings
indicate that palmitoylation-mediated localization and in-
tracellular trafficking of BMPR1a at site C180 affects non-
canonical, ERK-dependent BMP signaling (30).
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C180 S-Acylation of BMPR1a Alters Fate of NSCs In Vivo. To probe
potential effects of altered BMPR1a palmitoylation on NSC
activity and fate, we isolated embryonic NSCs at E17.5 and an-
alyzed their functional properties. We found that C180A muta-
tion caused enhanced NSC proliferation in vitro, as measured by
EdU pulse labeling (Fig. 4A). Furthermore we found increased
levels of key markers of oligodendrocytic differentiation and
maturation, OLIG2 (oligodendrocyte transcription factor) and
NG2 (neural/glial antigen 2), after 1 and 4 d of in vitro differ-
entiation by Western blotting (Fig. 4 B and C and SI Appendix, Fig.
S4A). Analysis by immunocytochemistry against NG2 confirmed
that more NG2+ cells were present after 4 d of in vitro differenti-
ation at the expense of a reduced number of GFAP+ (glial fibrillary
acidic protein) cells (Fig. 4D), indicating that acylation-deficient
C180A cells show an altered NSC behavior with increased oli-
godendrogenesis. Thus, our findings give direct evidence that
BMPR1a S-acylation is an essential modulator of NSC activity
and fate choices in vitro.
We next analyzed the effects of the C180A BMPR1a mutation
within the mouse brain. Given the in vitro phenotype of enhanced
Fig. 2. BMPR1a is S-acylated at 3 distinct sites by palmitoyl-transferase zDHHC20. (A, Upper) CRISPR/Cas9-mediated tagging of endogenous Bmpr1awith Gfp,
followed by an ABE assay where the palmitate was exchanged for a biotin (yellow). (A, Lower) ABE assay of wild-type and GFP-tagged BMPR1a knock-in NSCs
revealed that BMPR1a (red) is S-acylated (green). (B, Upper) During the acyl-PEG exchange, palmitate groups were exchanged for PEG groups, leading to a
defined increase in mass for every exchanged group. (B, Lower) Acyl-PEG exchange showed that BMPR1a is S-acylated at 3 distinct sites (blue stars). The red
star indicates the unmodified BMPR1a fraction. (C) Schematic showing the localization of S-acylated sites within BMPR1a: 2 of the S-acylated sites (cysteine
C173/C175) are based in the transmembrane domain. The site at C180 is located in the cytoplasmatic part of the receptor close to the transmembrane domain.
Quantification of acyl-PEG analyses showed that BMPR1a is mainly present in its lipidated form. Unmodified protein (black), monopalmitoylated (gray),
dipalmitoylated (green), tripalmitoylated (blue). (D) Coimmunoprecipation and mass spectrometry–based analysis of overexpressed BMPR1a and mutated
BMPR1a interaction partners in NSCs showed that impaired S-acylation does not affect the ability of BMPR1a to bind to its ligand, BMP4 (gray). Single spectral
counts of interacting BMPR2 were also detected, and tdTomato was used to control for unspecific enrichment. SC, spectral counts. (E) Overexpressed BMPR1a
(red) and zDHHC20 (green) colocalized in cultured NSCs. Nuclei were counterstained with DAPI. (F) Overexpression of zDHHC20 (gray; graph) together with
wild-type BMPR1a or BMPR1a harboring mutated sites of palmitoylated cysteines led to increased incorporation of 17-ODYA (green; blots) into BMPR1a,
BMPR1a C180A, and BMPR1a C173/175A (red; blots), indicating that all 3 S-acylated sites are responsive to zDHHC20 levels. 17-ODYA, alkyne linked palmitate
ortholog (17-octadecynoic acid). (Scale bar, 15 μm.) Error bars represent mean ± SD. **P < 0.01.














oligodendrogenesis, we analyzed the generation of late embryonic/
early postnatal oligodendrocytic cells. Therefore, we injected
E17.5 C180A and control mice with the thymidine analog BrdU
and analyzed the number and fate of BrdU-labeled cells in post-
natal brains at postnatal day 7 (P7). Corroborating the in vitro
data, we detected an increased density of OLIG2+ cells in the
corpus callosum and an increase in the BrdU+/OLIG2+ fraction of
BrdU+ cells as well as an increase in the NG2+/KI67+ fraction of
NG2+ cells in the cortex of P7 C180A mutant mice compared to
controls (Fig. 4 E and F). Thus, the observed increased oligoden-
drogenesis appears to be based on increased differentiation toward
the oligodendrocytic lineage and an increase in proliferation of oli-
godendrocyte precursor cells.
Strikingly, we also found an increased density of OLIG2+, NG2,
and APC+ (adenomatous polyposis coli) cells in the cortex (Fig.
5 A, C, and D), corpus callosum (Fig. 5 E and F), and hippo-
campus of adult mice (SI Appendix, Fig. S4B), confirming and
extending the phenotype we had observed in the P7 postnatal
brain (Fig. 4E). Interestingly, we found no differences in the
number of NeuN-expressing neurons in the cortex (Fig. 5B) or
in NSC activity (SI Appendix, Fig. S4C) in the neurogenic niche
of the adult hippocampus that were not permissive for oligo-
dendrogenesis (32) in C180A mutant mice compared to con-
trols, suggesting that the palmitoylation-dependent function of
BMPR1a requires the physiological oligodendroglial fate po-
tential of endogenous NSCs.
Fig. 3. Palmitoylation at C180 is important for BMPR1a function. (A) Schematic of genomic changes introduced into the Bmpr1a C180A transgenic knock-in
mouse. The genetic sequence coding for cysteine 180 of BMPR1a was altered to encode for an alanine. BMPR1a is expressed (green) at E17.5 in the ventricular
zone and colocalizes with the stem cell–associated intermediate filament NESTIN (red), as assessed by immunohistochemistry. VZ, ventricular zone; IZ, in-
termediate zone; CP, cortical plate. (B) BMPR1a cell surface expression is reduced in Bmpr1a C180A–mutated NSCs (gray), as measured by cell surface protein
biotinylation. The cell surface protein β-dystroglycan (β-DG) was used for normalization and to compensate for different reaction efficiencies. GAPDH and
BMPR1a in the input and unbound fraction revealed a comparable loading and efficient enrichment of BMPR1a. IP, immunoprecipitation; IN, input fraction;
UB, unbound fraction. (C) BMPR1a expression is unchanged in NSCs extracted from control (white) and Bmpr1a C180A (gray) embryos (E17.5). (D) The mobile
fraction of overexpressed BMPR1a C180A is decreased compared to BMPR1a. Shown are FRAP experiments using BMPR1a-mNeonGreen-3HA (control) and
BMPR1a-C180A-mNeonGreen-3HA. Note the reduced mobile fraction in C180A BMPR1a. (E) The rate of BMPR1a endocytosis, as measured by reversible
biotinylation, is reduced in NSCs extracted from Bmpr1a C180A (gray) embryos compared to controls (white). The cell surface protein β-DG undergoing
regular endocytosis was used as a loading control to normalize between sample-dependent differences in reaction efficiencies. (F) Noncanonical BMP sig-
naling is affected in the Bmpr1a C180A knock-in NSCs (gray) compared to control cells (white), indicated by reduced active ERK 1/2 in knock-in cells. (Scale
bars: 100 μm.) Cont, control. Error bars represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
We showed that a large number of proteins are palmitoylated in
mammalian NSCs. Thus, we provided a palmitoylation-proteome
resource that will be helpful in discovering mechanisms of NSC
control in the embryonic and adult mammalian brain. We focused
on BMPR1a, newly discovered to be palmitoylated in NSCs, and
showed that BMPR1a is modified by zDHHC20–mediated S-
acylation of 3 cysteine residues that affect BMP signaling in vitro
and in vivo. Thus, we provided direct in vivo evidence of NSC-
associated palmitoylation of a target protein that affects the fate of
mammalian NSCs. Future studies will aim to probe if enhanced
oligodendrogenesis in C180A mice may also cause enhanced remye-
lination in the context of demyelinating lesions, which may open
novel avenues to enhance myelin repair in the adult brain (33).
The identification of palmitoylation of BMPR1a may have
broad consequences for our understanding of health and disease
given that BMP signaling has been implicated in a large number
of biological processes ranging from stem cell–associated dif-
ferentiation to cancer growth (23, 34). Whether BMPR1a S-
acylation is affected in disease states will need to be determined.
Notably, palmitoylation of BMPR1a is not specific to NSCs, as
we also found acylation of the receptor in pluripotent ESCs (SI
Fig. 4. Genetic Bmpr1a C180A exchange promotes oligodendrogenesis in vitro and in vivo. (A) NSCs extracted from Bmpr1a C180A mice (gray) show increased
proliferation compared to controls (white), as measured using EdU pulse labeling (red). Nuclei were counterstained with DAPI (blue). (B and C) In vitro differ-
entiation of knock-in NSCs (gray) and control cells (white) revealed enhanced expression of the oligodendrocyte lineage proteins OLIG2 (B) and NG2 (C) after 1 and
4 d. GAPDH was used as a loading control at day 1 and TUBA4A at day 4 due to incompatibility with other antibodies used at day 4. (D) In vitro differentiation of
knock-in NSCs (gray) and control cells (white) revealed an elevated number of NG2+ cells (green) and a decreased number of GFAP+ cells (red) after 4 d, as analyzed
by immunocytochemistry. (E) Bmpr1a C180A mice (gray) showed a higher density of OLIG2+ cells in the corpus callosum compared to control mice (white) and an
increase in the BrdU+/OLIG2+ fraction of BrdU+ cells in the cortex at P7 (white; analyzed cortical and corpus callosum areas are marked). (E, Lower) High-power
magnifications of the areas marked by white squares. (F) Bmpr1a C180Amice (gray) show a an increase in the KI67+/NG2+ fraction of NG2+ cells in the cortex at P7.
(Scale bars, 50 μm [A and D, Lower], 100 μm [D and F], and 500 μm [D, Upper]). Cont., control. Error bars represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.














Appendix, Fig. S2 C–F). Unfortunately, exchange of cysteines
C173/175 into alanines may be nonviable in mice, hindering
in vivo analyses at this time. However, the findings that palmi-
toylation of C173/175 seems to be required for proper embryonic
development further support the notion that palmitoylation of
BMPR1a is of substantial functional relevance and that C173/175 S-
acylation is required for canonical BMP signaling, whereas S-
acylation of C180 affects noncanonical BMP signal transduction.
Future studies will need to use either conditional or in vitro ap-
proaches to exchange S-acylated cysteines on both alleles, which
Fig. 5. S-acylation of BMPR1a at C180 regulates the number of oligodendroglial cells in the adult brain. (A) Adult Bmpr1a C180A mice (gray) show a higher
number of OLIG2+ cells per mm2 compared to control mice (white). Black dotted lines indicate the analyzed cortical area. (B) C180A mutation in Bmpr1a
C180A mice (gray) does not affect the total number of neurons in the neocortex. Shown is the number of NeuN+ cells (black) per mm2 in mutant mice (gray)
and controls (white). (C and D) The number of NG2+ (C, black) and APC+ (D, black) cells increase in the cortex of Bmpr1a C180A mice (gray) compared to
control mice (white). (E and F) The number of NG2+ (E, black) and APC+ (F, black) cells in the corpus callosum increases in Bmpr1a C180A mice (gray) compared
to controls (white; analyzed area in the corpus callosum is marked). (G) BMPR1a is S-acylated at 3 distinct sites proximal to the transmembrane domain. The
substitution of cysteines 173 and 175 with non-S-acylatable alanines affects canonical BMP signaling (Upper Right), while mutating cysteine 180 affects
BMPR1a trafficking and noncanonical BMP signaling, leading to increased oligodendrogenesis in vitro and in vivo (Lower Right). (Scale bars: 250 μm [A and B]
and 500 μm [C–F]). Cont., control. Error bars represent mean ± SD. *P < 0.05, **P < 0.05, ***P < 0.05.
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may allow more in-depth functional analyses of the C173/175 sites.
As we showed, in vivo manipulation of palmitoylation of BMPR1a
seems to selectively affect BMP signaling, resulting in enhanced
generation of oligodendrocytes, and our in vitro data suggest that
this is based on altered noncanonical BMP signaling.
BMP receptors are present at the cell surface as hetero- or
homomeric complexes (35), and while BMPR1a mainly associates
with detergent-resistant membrane (DRM) fractions, BMPR2 was
reported to localize to DRM and non-DRM compartments (36).
However, it remains poorly understood how shifts between ca-
nonical and noncanonical BMP signaling are regulated (37–39). A
prerequisite for SMAD-independent signaling is the presence of
BMPR1 in cholesterol-rich microdomains regulating lateral mo-
bility of type I receptors, which has been described to be crucial for
regulating noncanonical BMP signaling without affecting canoni-
cal signaling function (36, 40). Thus, future studies are necessary
to address the impact of BMPR1a S-acylation on its segregation to
specific membrane fractions, its mobility, and the formation of
receptor complexes.
We used a screening approach to identify palmitoylated pro-
teins in mammalian NSCs. We showed that BMPR1a is S-
acylated and that palmitoylation affects the functionality of the
BMP signaling pathway that is critically involved in a variety of
cell biological processes (Fig. 5G). Manipulating palmitoylation
of BMP signaling components may represent an approach to
targeting BMP function in health and disease.
Materials and Methods
Stem Cell Cultures. Primary adult mouse NSCs were kept in the presence of
EGF (20 ng/mL), FGF-2 (20 ng/mL), and heparin (5 mg/mL) in a monolayer
culture at 37 °C and 5% CO2. DMEM/F12 GlutaMax supplemented with an-
tibiotics (Anti-Anti) and N2 was used as a standard medium. For some culture
conditions, an overnight BMP4 treatment was performed as described ear-
lier (41). For the generation of E17.5 cortical NSC cultures, pregnant Bmpr1a
C180A and control dams were killed at E17.5. E17.5 NSCs were kept in
DMEM/F12 GlutaMax, N2/B27 supplement, EGF (20 ng/mL), and FGF-2 (20 ng/mL)
at 37 °C and 5% CO2. Experiments performed with control or BMPR1a
C180A–derived E17.5 NSCs were performed with at least 4 biological repli-
cates, derived from different E17.5 embryos. ESCs (ESC line E14, isolated
from mouse strain 129P2/OlaHsd) were cultured in DMEM/F12/GlutaMAX
medium supplemented with N2, B27, antibiotics, and LIF (1,000 U/mL), 1 μM
PD0325901, and 3 μM CHIR99021 at 37 °C and 5% CO2. Cells were kept in
flasks coated with 0.2% (vol/vol) gelatin. Differentiation of ESCs was per-
formed as described earlier (42).
Acyl-Biotin Exchange Assay and Mass Spectrometric Analysis. The protocol was
performed as previously described (18). Please refer to the SI Appendix for a
more detailed description. Samples were adjusted to the same volume and
concentration (5 mL and 2.2 mg/mL) by the addition of LB. Sample prepa-
ration, liquid chromatography (LC) –MS/MS analysis, and data analysis were
performed as described previously (41) with some minor changes: raw files
were processed with Progenesis QI for proteomics (Nonlinear Dynamics) and
Gapdh, Actin, and Tubulin were used for normalization between samples.
These proteins bind due to their high abundance to the beads in a palmitoylation-
independent manner and can therefore be used to normalize between
samples and prevent detection of false-positive proteins. Mascot was used
for searching a target-decoy mouse database downloaded from Uniprot
(May 31, 2018). Parameters were set as follows: peptide tolerance ±10 ppm,
MS/MS tolerance ±0.7 DA, variable modifications: Acetyl (Protein N-term),
Carbamidomethyl (C), Gln→ pyro Glu (N-term), N-Ethylmaleimide, Oxidation
(M). Resulting Mascot data files were imported into Scaffold 4 (Proteome
Software). The threshold was set for peptides at 95% and for proteins at
99%. Decoy hits were excluded, and protein quantification and statistics
were exported as CSV files. To visualize the data, raw data with the value
0 were replaced with the value 10 and maximal fold chance was limited to
250, followed by a log2 transformation of all values. Log2 intensities be-
tween 5 and 35 were included in the graph. Gene names, P values, and
normalized protein abundance were exported to Metacore 6.37 build 69500
(Clarivate Analytics), and an enrichment analysis was performed. GO locali-
zation and GO molecular function results were then exported as an XLS file.
Data were visualized using GraphPad Prism 8. Identified candidate proteins
(that were significantly and at least 4-fold enriched over −HAM) were
compared to the SwissPalm database (April 24, 2019). Experiments were
performed in triplicates. For mass spectrometric analysis of coimmunopre-
cipitations, the same setup and protocol were used as described earlier, with
some modifications: When performing the mascot search, Carbamidomethyl
(C) was set as fixed and acetyl (Protein N-term), Gln→ pyro Glu (N-term), and
Oxidation (M) as variable modifications. Block randomization was per-
formed, and samples were measured in duplicates. Search results were then
analyzed by spectral counting using Scaffold 4 (Proteome Software). The
mass spectrometry proteomics data have been deposited in the Proteo-
meXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD014355.
Image Analysis. Image analysis was performed using Fiji imaging analysis
software (43), ZEN 2 (Carl Zeiss), or Imaris (Bitplane). All quantifications were
performed in a blind manner. The detailed procedures are provided in the
SI Appendix.
Statistical Analysis. Statistical analysiswas performedusing Prism8.1 (GraphPad).
For the comparison of 2 samples, we used unpaired t tests. If the variance of the 2
compared samples was significantly different, unpaired t tests with Welch’s
correction were used instead. Experiments where the controls were set to the
value 1 were analyzed by nonparametric testing using a Kolmogorov-Smirnov
test. For comparisons involving more than 2 samples, we used 1-way ANOVA
analysis followed by Sidak’s multiple comparison test.
Other materials and methods are provided in the SI Appendix, Materials
and Methods. All data are presented in the main file and the SI Appendix,
Figs. S1–S4 and Table S1. The mass spectrometry proteomics data have been
deposited in the ProteomeXchange Consortium via the PRIDE partner re-
pository with the dataset identifier PXD014355.
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